Cell therapy crossed into autoimmune disease.
CD19 CAR-T and related immune-reset approaches now have human remission signals and expanding trials.
ImmunologyImmune resetFibrosis resolutionNeuro-immune control
Immunology
As of June 2026, immunology is moving from chronic suppression toward immune-state reset, tissue-resolution logic, and circuit-mediated control. Autoimmune CAR-T, fibrosis reversal, vagus-mediated inflammation control, and immune-aging programs all raise the same buyer question: which immune state changed, and can it stay changed safely?
Domain research lens
This page tracks immune reset durability, tissue sanctuary risk, fibrosis reversibility, closed-loop substitution, and whether remission is mechanistically explained or only observed.
June 2026 field state
A field testing whether immune state can be reset instead of chronically suppressed.
The strongest work measures whether interventions remove pathogenic memory, restore regulation, resolve tissue injury, and avoid rebound, infection, malignancy, or organ toxicity.
Immune state, inflammatory memory, tolerance, autoimmunity, fibrosis, tissue resolution, neuro-immune control, and durable immune intervention endpoints.
The domain thesis: durable immunology value comes from knowing which state was reset, which sanctuary remains, and which tissue endpoint proves resolution.
Resolution biology is becoming a program variable.
Fibroblast states, macrophage programs, extracellular matrix dynamics, and tissue mechanics can be mapped more specifically.
Durability is not solved by remission.
Programs still need reconstitution, relapse, sanctuary, infection, and malignancy gates before they can claim immune reset.
Recent research signals
The 2025-2026 update is a decision-gate wave.
Each signal below starts from the field: what changed, why it matters, and which research or buyer decision becomes more testable.
Autoimmune cell therapy moved from striking cases to trial discipline.
Published and reported lupus experience continues to show remission potential, including severe cases treated with engineered T-cell approaches.
Why it matters
The buyer question is whether remission survives B-cell return, tissue sanctuary, immune reconstitution, and scalable manufacturing.
Decision implication
Changes platform review from potency to reset durability and control.
Vagus-mediated immunomodulation became a randomized test case.
RESET-RA tested vagus nerve-targeted neuromodulation in a randomized sham-controlled rheumatoid arthritis trial.
Why it matters
Bioelectronic immune control needs indication-by-circuit logic, measurable biomarkers, and substitution value.
Decision implication
Changes whether neuro-immune devices are monitored, partnered, or avoided.
AI-derived antifibrotic validation raised the bar for fibrosis programs.
A randomized Phase 2a trial of a generative-AI-discovered TNIK inhibitor in idiopathic pulmonary fibrosis was published in Nature Medicine.
Why it matters
Fibrosis programs need to prove restoration of resolution biology rather than only slowed matrix accumulation.
Decision implication
Moves target diligence toward organ context, reversibility, and endpoint hierarchy.
Immune aging is becoming a supply-chain problem.
Programs increasingly connect thymic output, clonal expansion, myeloid skew, senescence, infection risk, vaccine response, and tissue repair.
Why it matters
The actionable question is which immune node limits resilience, not whether an immune marker changes with age.
Decision implication
Changes next-study design toward resilience-limiting node classification.
What leading groups are working on
The current edge is a set of validation programs, not a single breakthrough story.
These representative programs and research fronts frame the active field before the page maps Zemi Dossiers into it.
Autoimmune CAR-T
CD19 immune reset moves into basket-trial discipline
CASTLE-style studies and NHS lupus experience are turning dramatic remission cases into questions about dose, lymphodepletion, B-cell return, relapse, and scalable manufacturing.
Cell therapy controlTransient and switchable immune reset strategies
mRNA, controllable, and alternative-target cell therapies are trying to preserve remission logic while reducing prolonged aplasia, CRS/ICANS, and bespoke manufacturing burden.
Fibrosis biologyResolution, repair, and matrix remodeling as measurable states
IPF and multi-organ fibrosis programs are testing whether fibroblast, macrophage, endothelial, matrix, and tissue-mechanics states can be reversed rather than just slowed.
Bioelectronic medicineVagus-mediated immunomodulation as a randomized test case
RESET-RA makes neuromodulation a serious immunology surface, but the field still needs biomarkers, indication-by-circuit logic, and substitution economics.
Immune resilienceAging immune systems as supply-chain failure
Thymic output, clonal hematopoiesis, myeloid skew, infection risk, vaccine response, and repair capacity are being connected into resilience-limiting node maps.
Decision gates
What must be true before a buyer should build, fund, partner, monitor, avoid, or run the next study.
These are field-level gates first. The dossier library appears later as the set of existing Zemi products that can help investigate them.
Reset durability
Does remission survive immune reconstitution and steroid withdrawal?
Sanctuary risk
Which tissue or immune compartment remains pathogenic after apparent reset?
Resolution proof
Does tissue function improve, or only the inflammatory marker?
Control layer
Can a device or cell therapy be dialed, stopped, or rescued?
Safety reserve
Are infection, malignancy, cytokine, and organ-toxicity risks bounded?
Endpoint hierarchy
Which biomarker, tissue, function, or relapse endpoint decides the next study?
Zemi Dossiers in this domain
The dossiers sit where new research creates hard buyer decisions.
Each dossier card uses stats from the actual research report manifest and Evidence & Decision Workbook, including pages, workbook sheets, evidence/source rows, claim rows, power rows, and decision instruments where present.
Primary Zemi Dossier
Cell Therapy for Autoimmune Disease
Distinguishes remission achieved from durability solved by mapping persistence, sanctuary, and immune reconstitution risks.
Why it belongs here
Which autoimmune cell-therapy programs have a credible durability path, and what would reveal relapse risk before scale-up?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Primary Zemi Dossier
Fibrosis as Failed Resolution
Identifies the rate-limiting resolution node and the matched research move across persistence, scar integrity, and reversal measurement.
Why it belongs here
Which fibrosis programs target the binding resolution node, and what would show whether repair can occur without destabilizing tissue integrity?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Primary Zemi Dossier
Immune Aging Supply Chain
Routes immune-aging programs to the binding supply-chain node before treating broad immune decline as one therapeutic target.
Why it belongs here
Which immune-aging interventions target the binding node, and when would restoration create more risk than resilience?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Neurodegeneration Convergence
Uses convergent detection to subtype disease, while requiring sign-labile biology and therapeutic-window logic before treatment spend.
Why it belongs here
Which neurodegeneration programs are using convergence for detection while still measuring the divergent biology needed for treatment decisions?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Bioelectronic Neuro-Immune Closed Loop
Scores indication readiness by biomarker validity, sensing fidelity, decoding generalizability, circuit match, and substitution economics.
Why it belongs here
Which indications have enough biomarker, sensing, decoding, and reimbursement logic to justify a closed-loop bioelectronic program?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
MRD-Guided Neoantigen Vaccines
Links MRD timing, antigen selection, vaccine manufacture, immune response, and recurrence endpoints into a recurrence-prevention decision gate.
Why it belongs here
Which MRD-guided vaccine strategies have enough timing, manufacturing, immune-response, and endpoint logic to justify next-step validation?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Next-Generation Immuno-Oncology Platforms
Separates IO platform promise from therapeutic-index reality across potency, specificity, resistance, safety, and combination logic.
Why it belongs here
Which next-generation IO programs improve therapeutic index rather than simply adding potency, complexity, or combination burden?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Xenotransplantation Durability Ceiling
Maps the durability ceiling across host tolerance, organ-specific failure physiology, immune compatibility, and organ-scale function.
Why it belongs here
Which xenotransplantation programs are limited by host tolerance, organ-specific failure physiology, perfusion, or immune compatibility rather than edit count?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Watchlist
Signals that would change the map in 2026-2028.
These are the developments most likely to change the field map, evidence posture, or next-study priorities.
Immune reset
Controlled autoimmune CAR-T readouts beyond case series
The field needs relapse timing, immune reconstitution, steroid-free remission, and severe-adverse-event rates across diseases.
FibrosisOrgan-specific reversal endpoints
A credible antifibrotic program should show function or structure moving in the right tissue, not only a biomarker trend.
Neuro-immuneClosed-loop biomarkers that generalize across inflammatory indications
Reusable sensing and control layers would change bioelectronic medicine from device feature to therapeutic platform.
Immune agingResilience markers tied to infection, vaccine, or therapy response
Markers become actionable only when they predict a modifiable failure in defense, repair, or treatment tolerance.
Field-note discipline
Current-state pages need a source-aware update layer.
The public page stays readable, but the underlying domain model tracks source-linked developments that change evidence posture, buyer decisions, or next-study priorities.
2025-2026 / Autoimmune CAR-T
Autoimmune cell therapy is a durability problem, not just a remission headline.
The decisive evidence will be what happens after immune reconstitution and across tissue sanctuary sites.
2025 / RESET-RA Randomized neuro-immune modulation gives the domain a device benchmark.Future claims should specify the biomarker, circuit, dose rule, and patient-selection logic, not only stimulation feasibility.
2025 / Fibrosis AI-discovered fibrosis drugs still have to prove resolution biology.The domain signal is stronger when target discovery, tissue state, function, and endpoint sensitivity line up.
From domain signal to Zemi Dossier
Request access to inspect the full research report, Evidence & Decision Workbook, power calculations, and release-audit surfaces behind each decision package.